1. Systemic Lupus Erythematosus

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Understanding and Treating SLE Current Regimens Manage Symptoms, Not Disease

4. SLE and the Risk of Organ Damage

5. A Lifelong Threat Risk for Organ Damage Remains High

6. A Lifelong Threat Risk for Organ Damage Remains High (cont)

7. Flare Vigilance Fewer Flares Means Less Organ Damage

8. Pathogenesis of SLE

9. Detection of Autoantibodies Before Diagnosis

10. Genetic Component to SLE

11. Epigenetics and Rheumatic Diseases

12. Environmental Agents Implicated in Induction or Activation of SLE

13. Pathophysiology of SLE

14. B-Cell Function in Immune Responses

15. Targeted Therapies for B-Cell Depletion

16. Targeted Therapies for Inhibiting BLyS

17. Meeting the Primary Endpoint SRI Response Rate

18. Other Agents Promising and Not So Promising

19. Summary of B-Cell Therapies

20. Pathophysiology of SLE T-Cell Function

21. Targeted Therapies T-Cell Pathways

22. Targeted Therapies T-Cell Pathways (cont)

23. Targeted Therapies T-Cell Pathways (cont)

24. Physiologic Role of IL-17

25. Cytokines

26. Inhibition of IFN-α May Provide Therapeutic Benefit for Patients With SLE

27. The Human Kinome Blocking Cell Surface Receptors

28. Other Emerging Therapies and Mechanisms of Action Under Investigation

29. Concluding Remarks

30. Concluding Remarks (cont)

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)

34. Abbreviations (cont)